Estriol Therapy for Post-Partum Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis are ineffective in addressing clinical symptoms and disease progression, and hormone therapies have shown mixed results with potential side effects, while existing hormone treatments do not adequately replicate the beneficial effects observed during pregnancy.
Innovation Solution
Administration of a selected dose of estriol, either alone or in combination with progesterone and other immunotherapeutic agents, to mimic the hormonal environment of late pregnancy, thereby reducing autoimmune disease symptoms and progression by modulating the immune system's cytokine balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then disease symptoms are addressed, but they are ineffective in addressing disease progression and have mixed results with potential side effects
Solution Approach 1:
The patent changes the hormonal parameters by administering estriol at specific doses (e.g., 1-10 mg/day) to replicate pregnancy-level estrogen concentrations, thereby shifting the immune system from a Th1-dominant state to a Th2-dominant state. This parameter change in hormone levels achieves reliable disease control without the harmful side effects of conventional immunosuppressants
Solution Approach 2:
The patent uses estriol as an intermediary substance that mediates between the immune system and the disease process. By introducing this hormonal intermediary, the treatment achieves disease control through immune modulation rather than direct suppression, reducing harmful side effects while maintaining reliability
2Reliability
If hormone therapies are administered to replicate pregnancy effects, then autoimmune disease symptoms improve, but existing hormone treatments do not adequately replicate the beneficial effects of pregnancy
Solution Approach 1:
The patent specifically targets pregnancy-related parameters by administering estriol at doses and concentrations that replicate the hormonal environment of pregnancy. This includes achieving serum estrogen levels comparable to late pregnancy (e.g., 1-10 mg/day estriol), thereby accurately reproducing the immune-modulating effects that occur naturally during pregnancy
Solution Approach 2:
The patent employs periodic administration of estriol to maintain sustained pregnancy-like hormonal levels throughout the treatment period. This periodic dosing strategy ensures continuous replication of pregnancy effects, achieving reliable symptom improvement that matches the natural protective effect of pregnancy
3Reliability
If estriol is administered at pregnancy levels, then Th1 cytokines decrease and Th2 cytokines increase, but the dosage and administration method must be optimized
Solution Approach 1:
The patent optimizes the dosage parameter of estriol administration to achieve the desired cytokine balance. By establishing specific dosage ranges (e.g., 1-10 mg/day) and administration schedules, the patent simplifies the complexity of dosage optimization while maintaining reliable Th1/Th2 cytokine modulation
Solution Approach 2:
The patent incorporates feedback mechanisms to monitor and adjust estriol dosage based on individual patient response and cytokine levels. This feedback approach simplifies dosage optimization by using measurable outcomes (cytokine profiles, symptom improvement) to guide treatment adjustments
Data Source
AI summary
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.